J.P. Morgan Healthcare Conference Presentation

Focus on prevention and treatment, with performance momentum GSK Q3 and 9 months 2023 delivered double digit sales and adjusted operating profit growth 1.2 GSK Strong performances from key products led by outstanding launch of first ever RSV vaccine Arexvy Approvals across Specialty Medicines strengthening new product portfolio Nearly £8 billion of sales in 9 months 2023 from products launched since 20173 and 70% of business now in Vaccines and Specialty Medicines 1. Excluding COVID-19 solutions 2.9m year-to-date 2023 financials 3. New products launched since 2017 delivered £7.8 billion 9m 2023 and include: Zejula, Trelegy, Shingrix, Juluca, Dovato, Duvroq, Rukobia, Blenrep, Cabenuva, Jemperli, Apretude, Arexvy 3

View entire presentation